(02) 9850 4000
  • Linkedin
  • Twitter
  • Linkedin
  • Twitter
We are Minomic
  • Home
  • Company
    • Management
    • Board
    • Clinical Advisory Panel
    • Shareholder Information
    • Financial Statements
  • Diagnostics
  • News
  • Contact Us
Select Page
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer

ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer

by Minomic | Feb 14, 2018

Facebook Twitter Google+ LinkedIn A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic’s head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary...

Recent Posts

  • Minomic Signs Agreement with US Pathology Laboratory
  • Minomic announces completion of demerger of GlyTherix Ltd
  • Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China

SHAREHOLDER NEWSLETTER

Minomic Shareholder Update Q4 2018

Minomic Shareholder Update Q3 2018

ANNUAL FINANCIAL STATEMENTS

2018 Annual Report

 

 

FOR SHAREHOLDERS

Change of Address Form

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

Would you like to talk with Minomic about:

  • Partnering with us to take our products to your markets?
  • Investing in us?
  • Media or upcoming events?
  • Some feedback that you have?
Tweets by MinomicInt

RECENT POSTS

  • Minomic Signs Agreement with US Pathology Laboratory
  • Minomic announces completion of demerger of GlyTherix Ltd
  • Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
  • Minomic secures key patent in the United States and China
  • Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
  • ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial

SHAREHOLDER NEWSLETTER

Minomic Shareholder Update Q4 2018

Minomic Shareholder Update Q3 2018

ANNUAL FINANCIAL STATEMENTS

2018 Annual Report

 

 

FOR SHAREHOLDERS

Change of Address Form

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

Would you like to talk with Minomic about:

  • Partnering with us to take our products to your markets?
  • Investing in us?
  • Media or upcoming events?
  • Some feedback that you have?
  • Home
  • News
  • Shareholder Information
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Linkedin
  • Twitter

COPYRIGHT 2018 | MINOMIC - ALL RIGHTS RESERVED